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Morphine, a mu-opiate agonist, and ethylketazocine, a kappa-opiate agonist, produce 
distinct behavioral, pharmacologic, and biochemical effects. In the mouse, large doses 
of morphine produce convulsions that are usually lethal and that cannot be blocked 
by naltrexone, whereas ethylketazocine produces nonlethal clonic convulsions that can 
be blocked by naltrexone. Moreover, mice made tolerant to morphine failed to show 
cross-tolerance to ethylketazocine, suggesting that the convulsions induced by these 
drugs are not mediated via a common opioid mechanism. Following a series of elec- 
troconvulsive shocks, both morphine and ethylketazocine produced clonic convulsions 
that were not lethal and that could be blocked by naltrexone. Furthermore, electro- 
convulsive shock-treated animals made tolerant to morphine-induced convulsions 
showed cross-tolerance to ethylketazocine. These data suggest that eletroconvulsive 
shock may alter kappa-opioid systems in such a way as to allow mu-agonists to be 
funCtiOnal at these Sites. 0 1986 Academic Press. Inc. 
INTRODUCTION 
Opiate receptor multiplicity is at present a well accepted concept in opiate 
pharmacology. It was introduced by Martin and his colleagues (9, 21) and 
was based in part, on the various behavioral syndromes induced by narcotic 
analgesics in the chronic spinal dog. Morphine-like compounds (mu-receptor 
agonists) produced miosis, bradycardia, hypothermia, and a general depression 
of pain responses. Ethylketazocine (EKC)-like compounds (kappa-receptor 
agonists) produced depression of the flexor reflex and sedation, but did not 
markedly alter pulse and respiration rate, body temperature, and skin twitch 
reflex. Further, morphine tolerance did not result in cross-tolerance to EKC, 
and EKC-like compounds failed to suppress signs of abstinence in the mor- 
Abbreviations: ECS-electroconvulsive shock, EKC-ethylketazocine 
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phine-dependent dog, again suggesting that morphine and EKC mediate their 
effects via different mechanisms. 
Those early findings were bolstered by more recent studies using other 
experimental animals or protocols. Tepper and Woods (28) demonstrated 
that whereas morphine produced a Straub-tail response and a dose-dependent 
increase in locomotor activity in the mouse, EKC failed to produce a Straub- 
tail response and induced a decrease in locomotion. Moreover, the induction 
of tolerance to EKC’s locomotor depressing effect did not result in cross- 
tolerance to morphine, indicating that the locomotor changes induced by 
these compounds are mediated by different mechanisms. Hein et al. (11) 
reported that EKC and morphine have different discriminative effects, as 
monkeys trained to discriminate EKC from saline showed drug-appropriate 
responding to other kappa-agonists, but failed to generalize to morphine, 
levorphanol, or codeine. Woods et al. (35) also dissociated EKC and morphine 
using the self-administration paradigm. They found that monkeys self-ad- 
ministered morphine-like drugs, but failed to self-administer EKC at rates 
above those maintained by saline. And finally, although both mu and kappa 
compounds produce analgesia, their sites of action in the nervous system have 
been shown to differ (34). Injections of mu-agonists in the periaquaductal 
grey produce analgesia, whereas similar injections of EKC do not. EKC 
was found to induce analgesia, however, when injected directly into the 
spinal cord. 
In addition to these findings, we recently found that mu- and kappa-agonists 
produce convulsions via different mechanisms in the mouse (20). Mu-agonists 
produced convulsions only at lethal doses, could not be blocked by naltrexone, 
and their order of potency was not consistent with established opiate receptor 
responses. Codeine was found to be more potent than morphine and levor- 
phanol failed to produce convulsions even at lethal doses. In contrast, studies 
using such endpoints as analgesia and locomotion consistently report that the 
descending order of potency is levorphanol. morphine, and codeine (25,29). 
Kappa-agonists (EKC and UM 1071), on the other hand, produced clonic 
convulsions that were not lethal, that could be blocked by naltrexone, and 
that were stereoselective. These findings suggested that the convulsions ob- 
served with mu-opiates may not be mediated by opiate receptors, and those 
induced by kappa-agonists appear to be a receptor-specific response. 
Following a series of electroconvulsive shocks (ECS) we found that animals 
showed a marked change in responsiveness to mu- and kappa-agonists (I 8- 
20). In contrast to the effects observed in normal animals, both mu- and 
kappa-agonists produced receptor-specific convulsions. In ECS-treated ani- 
mals, both mu and kappa compounds produced nonlethal, naltrexone an- 
tagonizable, clonic convulsions at significantly smaller doses than in normal 
animals. In addition, the relative effectiveness of mu-agonists was consistent 
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with other opiate responses; levorphanol was most potent followed by mor- 
phine and codeine. These results suggested that although mu- and kappa- 
agonists produce their convulsant effects via different mechanisms in normal 
mice, they may induce convulsions via a common opioid mechanism following 
ECS. To test this possibility, we examined whether or not the induction of 
morphine tolerance results in cross-tolerance to EKC’s convulsant effects in 
ECS-treated and normal animals. The appearance of cross-tolerance would 
indicate a common mechanism of action, and the lack of cross-tolerance 
would suggest independent mechanisms. 
We also extended our previous findings by examining the change in opiate 
responsiveness during the development of seizure proneness. Several reports 
have suggested that endogenous opioids are released either after or during 
seizure activity (13, 14, 16,24, 26, 30-32). It is possible, then, that a periodic 
release of opioids in association with seizures may be necessary for the in- 
duction of seizure proneness or kindling. We tested this hypothesis by treating 
animals with daily subconvulsive doses of EKC, morphine, or codeine to 
determine if normal animals would become sensitized to the convulsant effects 
of drugs. We characterized the convulsions produced by this procedure further 
by examining whether or not they are reversible by naltrexone and represent 
an enduring change in functioning. 
METHODS 
General Methods. All animals used were adult male C57BL/6J mice either 
bought from Jackson Laboratories, Bar Harbor, Maine, or bred in our lab- 
oratory from Jackson laboratory stock. The animals were maintained on a 
12-h light: 12-h dark cycle (lights on at 2200 h) with food and water available 
ad Ii&turn. All drug data points were based on a minimum of six animals 
that were randomly assigned to each drug condition. The animals were injected 
i.p. and the range of doses was based on the results from pilot experiments. 
The percentage of animals showing a generalized convulsion, including clonic 
limb movements and falling, was recorded for each condition and was used 
as the dependent variable in each of the experiments. 
The ECS-treated animals received seven daily electroconvulsive shocks and 
were tested at various times after their last convulsion. The ECS procedure 
consisted of passing electricity to the cornea (6.5 mA, 0.5 s) via two saline- 
soaked gauze pads that were attached to two wooden dowels. 
Experiment I. Morphine Tolerance and Cross-Tolerance to Ethylketazocine 
in Electroconvulsive-Shock- Treated and Normal Animals. Normal mice. Mor- 
phine tolerance was induced in a group (N = 19) of normal mice by injecting 
them three times daily (900, 1700, and 2400 h) with 100 mg/kg morphine 
for 3 days. On their 4th day of treatment, they were injected with 100 mg/kg 
morphine (900 h) and tested with EKC (3.0, 6.0, or 10.0 mg/kg) 4 to 6 h 
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later to examine if they were cross-tolerant. A separate group (N = 19) of 
animals received the same schedule of saline injections and were similarly 
tested with EKC (3.0, 6.0, or 10.0 mg/kg). The percentage of animals con- 
vulsing to EKC was recorded during a 30-min observation period. 
An additional two groups (N = 12 or 14) of normal mice were treated with 
chronic administration of morphine (100 mg/kg) or saline according to the 
schedule described above and tested with morphine (300 or 600 mg/kg) to 
examine whether or not the induction of morphine tolerance would alter an 
animal’s sensitivity to the convulsant effects of morphine. The percentage of 
animals convulsing to morphine (300 or 600 mg/kg) was recorded during a 
120-min test period. 
Electroconvulsive shock-treated mice. One day after their last of seven con- 
vulsions, ECS-treated animals (N = 26) received morphine injections twice 
daily (1000 and 1500 h). The animals initially received an injection of 30 
mg/kg morphine and were thereafter treated with doses of 100 mg/kg mor- 
phine. After each injection, the animals were observed and the percentage of 
animals convulsing was recorded during a 90-min test period. ECS-treated 
animals were considered to be tolerant when none convulsed to morphine 
(100 mg/kg) during two consecutive test periods. This criterion was reached 
after the sixth morphine injection. A second group (N = 18) of ECS-treated 
animals were similarly handled and treated with six saline injections. 
The morphine-treated ECS animals were tested the following day with one 
of several doses of EKC (3.0, 10.0, or 30.0 mg/kg) to determine whether or 
not morphine tolerance would result in cross-tolerance to EKC. The saline- 
treated ECS mice were similarly treated with 1.0. 1.7, or 3.0 mg/kg EKC. 
The percentage of animals convulsing to EKC was recorded during a 30-min 
test period. 
Recovery. The morphine-and saline-treated ECS animals were injected again 
with EKC (1.0, 1.7, or 3.0 mg/kg) 7 days after their cross-tolerance testing. 
The percentage of animals convulsing was recorded for 30 min following their 
injection. Three days later, the animals in both treatment groups were tested 
with morphine (10.0, 30.0, or 100.0 mg/kg) and observed for convulsions 
during a 90-min test period. 
Metrazol control. Because morphine-treated ECS animals showed cross- 
tolerance to EKC, we examined if these effects were due to a general decreased 
sensitivity to convulsant drugs. An additional two groups (N = 2 1 or 18) of 
mice received seven ECS and treated with six injections of morhpine or saline 
in accordance with the drug schedule described for electroshocked mice. The 
morphine- and saline-treated ECS animals were tested the following day with 
one of several doses of metrazol (35.0, 40.0, or 45.0 mg/kg) and observed for 
convulsions during a 30-min test period. 
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Experiment II. Repeated Opiate Administration and Seizure Proneness. 
Five groups (N = 7 or 8) of mice received daily injections of either mu (mor- 
phine, codeine)- or kappa (EKC)-opiates and were observed for convulsions. 
Groups I and II were injected for 20 days with either 100 or 170 mg/kg 
codeine, respectively, and were observed for 30 min. Groups III and IV were 
injected with either 100 or 300 mg/kg morphine, respectively, and were ob- 
served for 90 min. Group III’s drug treatment was extended to 3 1 days because 
one animal in this group started to convulse after receiving its 20th dose of 
morphine (100 mg/kg). Group IV was treated with morphine (300 mg/kg) 
for 20 days. Group V was injected with EKC (3 mg/kg) for 19 days and was 
observed for a 30-min test period. These doses of opiates were chosen because 
they had been found to produce convulsions in less than 20% of the normal 
animals (20) thereby providing a low baseline to test whether or not sensiti- 
zation occurs. The length of the observation period was determined by previous 
pilot data which indicated that convulsions did not occur beyond these time 
periods. 
As only repeated EKC administration resulted in a sensitization or kindling 
effect, we tested whether or not the EKC-induced convulsions were a receptor- 
mediated response and could be blocked by naltrexone pretreatment. The 
animals previously kindled with EKC were treated with either saline or nal- 
trexone (0.1, 0.3, 1 .O, and 3.0 mg/kg) on the alternate days 5 min prior to 
receiving EKC (3 mg/kg). This drug testing protocol took 8 days to complete 
(days 20 to 27). To examine whether or not the enhanced seizure proneness 
observed with EKC was “permanent” as has been described with electrical 
kindling (lo), the EKC-treated animals were tested again with EKC (3 mg/ 
kg) 30 (day 57) and 90 (day 117) days after the last naltrexone and EKC 
injection. 
RESULTS 
Experiment I. ECS animals receiving repeated doses of morphine showed 
tolerance to its convulsant effects (Fig. 1). Whereas 85% of the ECS animals 
convulsed following their first lOO-mg/kg injection of morphine, none con- 
vulsed after their fourth or fifth injection at this dose (x’ 38.13, P < 0.0 1). If 
circadian variation in morphine sensitivity is taken into account by comparing 
those injections administered at the same time in the light-dark cycle (injec- 
tions 1, 3, 5 or 2, 4, 6), one observes a gradual decline in the percentage of 
animals convulsing. In contrast, chronic morphine treatment failed to sig- 
nificantly alter the morphine-induced convulsion dose-response curve in 
normal animals (x2 2.4 at 300 mg/kg morphine, x2 1.66 at 600 mg/kg mor- 
phine, both n.s.). 
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Morphine-tolerant ECS mice showed cross-tolerance to EKC (Fig. 2, left). 
Whereas 84% of the saline-treated ECS animals convulsed to a 3-mg/kg dose 
of EKC, none of the morphine-treated ECS animals convulsed at this dose 
(x2 10.37, P < 0.01). Even doses as high as 30 mg/kg EKC produced con- 
vulsions in only 40% of the morphine-tolerant ECS animals. In contrast, 
normal animals who have been made tolerant to morphine failed to show 
cross-tolerance to EKC (Fig. 2, right). In fact, the data suggest that morphine- 
tolerant mice were more sensitive to EKC’s convulsant effect (x2 8.57, P 
< 0.01 at 6 mg/kg). 
The morphine-treated ECS animals showed a complete recovery to EKC 
7 days following their cross-tolerance testing. They also recovered their sen- 
sitivity to morphine and did not differ from saline controls in their respon- 
siveness to morphine when tested 3 days later. The cross-tolerance was not 
due to a general decreased sensitivity to convulsants as morphine-tolerant 
ECS animals were not less sensitive to metrazol (Fig. 3). 
Experiment II. Of animals treated with subconvulsive doses of morphine, 
codeine, or EKC, only those treated with EKC showed a robust kindling effect 
(Fig. 4). The percentage of animals convulsing to EKC gradually increased 
with daily administration and was at its maximum level after 13 injections. 
Although none of the animals convulsed to the first injection of EKC (3 mg/ 
kg), 86% of them convulsed after their 13th injection. The convulsions kindled 
with EKC appear to be receptor-mediated as they could be completely blocked 
. ECS Mice 
IN=261 
Or 
I 2 3 4 5 
MORPHINE (100 mg/kg) INJECTIONS 
FIG. 1. Percentage of electroconvulsive shock-treated (ECS) mice convulsing to morphine ad- 
ministered twice daily. The animals were initially treated with 30 mg/kg morphine and thereafter 
injected with a dose of 100 mg/kg (injections 1 to 5). 
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FIG. 2. Percentage of morphine-tolerant and saline-treated ECS and normal animals convulsing 
to ethylketazocine (EKC). All data points were based on six or more animals. 
by naltrexone (3 mg/kg) pretreatment (x2 7.78, P < 0.01). Further, this change 
in sensitivity to EKC seems to be “permanent” as animals tested at 1 month 
(six of seven animals convulsed) and 3 months (five of six animals convulsed) 
still showed the effect. In contrast, repeated daily injections of morphine (100 
or 300 mg/kg) failed to produce a kindling effect; only two of eight animals 
treated with 300 mg/kg and one of seven animals treated with 100 mg/kg 
morphine convulsed during this treatment protocol. Similarly, daily injections 
of codeine failed to produce a kindling effect, as none of the animals treated 
. ECS M~ceTreated With 
ctmnc t&r*m 
0 ECS MlceTreated 
: 
With Chronic Sohne 
(Total N=l91 
it or 
35 40 45 50 55 
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FIG. 3. Percentage of morphine-tolerant and saline-treated ECS mice convulsing to metrazol. 
All data points were based on six or more animals. 





FIG. 4. Percentage of normal mice convulsing to daily doses of morphine, codeine, or EKC. 
Lower doses of morphine (100 mg/kg) and codeine (100 mg/kg) were also administered daily to 
separate groups of mice. Because these smaller doses failed to produce a kindling effect, they were 
not included in the figure. 
with 100 mg/kg convulsed after 20 days of injections and only 2 of 7 convulsed 
with 170 mg/kg. Of the 2 animals that convulsed with codeine, one died 
during its first convulsion and the other died after its third convulsion. 
DISCUSSION 
These data suggest that morphine and EKC produce their convulsant effects 
by different mechanisms in naive animals, but function through a common 
opioid mechanism following the induction of convulsions. This conclusion 
is supported by the finding of a morphine-EKC cross-tolerance in ECS-treated 
mice and not in normal animals. In addition, as our work demonstrates (18- 
20), the convulsions induced by mu-opiates in normal animals are not re- 
ceptor-mediated, whereas those observed to follow ECS are receptor-specific. 
In normal mice, mu-agonists produce convulsions that are not reversible by 
naltrexone, usually lethal, and not altered by chronic morphine treatment. 
These findings are consistent with the report (22) that rats receiving repeated 
large systemic doses of morphine do not become tolerant to its seizure-inducing 
effects. In contrast, following ECS, mu-agonists induce convulsions that are 
nonlethal, reversible by naltrexone, and demonstrate tolerance and cross- 
tolerance to other opioids. Kappa-agonists, on the other hand, induce con- 
vulsions by an opioid receptor mechanism in both ECS and normal mice. 
The ability of naloxone or naltrexone to antagonize the convulsions induced 
by systemically administered mu-opioids remains a point of controversy in 
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the literature. Several reports have indicated that these convulsions are not 
antagonizable (15, 27), whereas others report that they can be blocked by 
opiate antagonists (1, 8). Undoubtedly, these results are likely to be due to 
species and procedural differences. However, it has been our experience that 
systemically administered mu-opiates have either not produced convulsions 
in normal mice or have produced convulsions that could not be blocked by 
pretreatment with an opiate antagonist. 
The question arises, then, as to how morphine and other mu-agonists which 
do not produce convulsions by an opiate receptor mechanism in normal 
animals, do so following ECS. One possible explanation is that ECS alters the 
selectivity of kappa-receptors in such a way as to allow mu agonists to be 
functional at these receptors. Several lines of evidence support this hypothesis. 
First, both mu- and kappa-agonists produce convulsions in ECS-treated an- 
imals that can be blocked by similar doses of naltrexone (1 to 3 mg/kg). 
Reversal of kappa-receptor-mediated effects characteristically requires sub- 
stantially larger doses of naloxone or naltrexone than required to reverse mu- 
receptor-mediated responses. Our finding that naltrexone was equally effective 
in blocking the convulsions induced by mu- and kappa-opiates argues for a 
common opiate mechanism of action. Second, although agonists, such as 
morphine, show a relative selectivity for mu-receptors, they have a substantial 
affinity for the kappa-receptor as well ( 17). In fact, the order of potency of 
mu-agonists observed in ECS-treated animals (levorphanol > morphine 
> codeine) is consistent with their affinity for kappa-receptors. Levorphanol 
was found to have greater affinity for kappa-receptors than morphine, which 
is well correlated with its greater effectiveness in inducing convulsions in ECS 
animals. And third, as the present study demonstrates, ECS animals made 
tolerant to morphine show cross-tolerance to EKC’s convulsant effects. The 
cross-tolerance observed was not due to an inherent difference between the 
morphine- and saline-treated animals in their sensitivity to EKC and morphine 
prior to initiating drug treatment, as the groups did not differ after a l-week 
recovery period. In addition, the cross-tolerance observed can not be explained 
on the basis of a general decreased sensitivity to convulsants, as morphine- 
tolerant ECS animals were not less sensitive to metrazol. 
The convulsant actions of EKC and morphine can be dissociated further 
in normal animals when administered daily. Of animals treated with daily 
subconvulsive doses of EKC, morphine, or codeine, only those animals treated 
with EKC showed a robust kindling effect. The EKC-kindled convulsions 
appeared to be a specific response as they could be blocked by naltrexone. 
Further, as seen with amygdala kindling, the change in sensitivity appears to 
be “permanent” as animals remained sensitized to EKC for at least 3 months. 
Whereas other investigators have suggested that morphine’s locomotor effect 
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in the mouse, an opiate receptor-mediated response, shows signs of sensiti- 
zation with repeated daily administration [for review, see (23)], our evidence 
demonstrates that this is not the case for morphine’s convulsant effect and 
suggests that the two effects may be mediated by different mechanisms. 
It is conceivable, therefore, especially in view of the epileptogenic properties 
ofthe endogenous opioids (4,6,7, 12,33) and the fact that their concentrations 
are elevated following a series of convulsions (13, 14, 16, 32), that they may 
play a role in the sensitization observed with the induction of convulsions. 
Elevation in the concentrations of dynorphin, an endogenous opioid peptide 
with a strong affinity for kappa-receptors (2, 3), following the completion of 
amygdala kindling (24) is particularly interesting in light of our data with 
EKC. These changes in dynorphin content persisted for at least 1 month 
following an animal’s last convulsion. 
It should be noted that the effects we observed with systemic administration 
of opiates are different from those observed with intraventricular injections. 
The seizure-inducing effects of morphine and endogenous opioid peptides 
observed in normal animals to follow intraventricular injections appear to be 
a specific receptor response. In contrast to systemic injections, intraventricular 
injections of morphine or opioid peptides produce seizures that are naloxone- 
reversible, show tolerance with repeated administration, and are not observed 
in morphine-tolerant animals [for review, see (5)J. These differences may be 
due to morphine’s different site(s) of action when systemic or intraventricular 
routes are used. 
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